MASHINIi

Cyclerion Therapeutics, Inc..

CYCN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines for serious and often rare diseases. The company focuses on modulating the nitric oxide (NO) pathway, a fundamental mechanism that plays a crucial...Show More

Ethical Profile

Mixed.

Cyclerion Therapeutics is dedicated to developing treatments for serious diseases, including cardiovascular and rare kidney conditions, through its sGC stimulator pipeline like Olinciguat and Praliciguat. This core mission aims to significantly improve health outcomes for specific patient populations. However, as a biopharmaceutical company, its drug development process inherently necessitates animal testing, a practice critics highlight as directly conflicting with animal welfare values. Reports suggest there is no public information available regarding Cyclerion's animal testing policies or investments in alternative methods. For other ethical considerations, such as fair pay, honest business practices, or environmental impact, there is insufficient public evidence to form a comprehensive ethical profile.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect10
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-30
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Cyclerion Therapeutics, Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on drug discovery and development. Its core business does not involve lending, insurance, or other financial services to consumers. The provided articles discuss patient assistance programs for medications but contain no information about the company's involvement in financial activities.

1
Therefore, all KPIs related to fair money and economic opportunity are not applicable.

Fair Pay & Worker Respect

10

As of September 30, 2025, and December 31, 2023, Cyclerion Therapeutics, Inc. had one employee and several consultants.

1
Due to this minimal workforce, several KPIs are not applicable or lack sufficient data for meaningful assessment, including living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, insecure contract share, and health insurance coverage. The company's small size also makes turnover rate metrics not meaningful. The company has a Glassdoor overall rating of 4.7 out of 5, with 100% of employees recommending it to a friend, indicating a high worker engagement score.
2
However, the company recorded total costs of approximately $1.3 million related to a workforce reduction of thirteen full-time employees in 2022, and approximately $0.6 million related to further workforce reductions in 2023, which are considered labor-law infractions.
3

Fair Trade & Ethical Sourcing

0

No information regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend was found in the provided article.

1

Honest & Fair Business

0

No evidence available to assess Cyclerion Therapeutics, Inc. on Honest & Fair Business.

Kind to Animals

0

No data directly related to Kind to Animals or animal welfare standards, policies, or practices for Cyclerion Therapeutics, Inc. was found in the provided documents.

1
Therefore, no KPIs under this value can be assessed.

No War, No Weapons

0

No evidence available to assess Cyclerion Therapeutics, Inc. on No War, No Weapons.

Planet-Friendly Business

-30

Cyclerion Therapeutics, Inc. and its subsidiary are in compliance with applicable environmental laws and regulations, and have received all required permits.

1
Since January 1, 2024, the company has not received any written notice alleging non-compliance with any environmental law, and there are no circumstances expected to interfere with future compliance.
2
The company also reports no material liability under any environmental law.
3
Cyclerion is committed to operating its business in a manner that protects the environment and complies with all applicable environmental laws, regulations, and industry best practices, including those affecting hazardous waste disposal, emissions, and water purity. Employees are expected to be aware of environmental issues and maintain compliance with internal environmental policies. The company does not own or operate manufacturing facilities, depending on third-party contract manufacturing organizations (CMOs) which are required to comply with current GMP requirements and environmental, health, and safety laws.
4

Respect for Cultures & Communities

0

No evidence available to assess Cyclerion Therapeutics, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

No evidence available to assess Cyclerion Therapeutics, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No evidence available to assess Cyclerion Therapeutics, Inc. on Zero Waste & Sustainable Products.

Own Cyclerion Therapeutics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.